NEWS RELEASES
YEAR
-
CANBRIDGE RECEIVES APPROVAL TO COMMENCE CAN008 PHASE II/III TRIAL IN GLIOBLASTOMA MULTIFORME (GBM) IN CHINA
APR 12, 2018
-
INDUSTRY VETERAN JOINS CANBRIDGE LIFE SCIENCES ADVISORY TEAM
FEB 13, 2018
-
PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA
FEB 02, 2018
-
CANBRIDGE APPOINTS SUNNY ZHANG AS VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY
JAN 16, 2018
-
CANBRIDGE LIFE SCIENCES SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR CAN017 TRIAL IN ESOPHAGEAL SQUAMOUS CELL CANCER (ESCC) IN CHINA
DEC 21, 2017
-
CANBRIDGE COMPLETES PATIENT ENROLMENT FOR PHASE I CLINICAL TRIAL OF CAN008 IN TREATMENT OF GLIOBLASTOMA MULTIFORME IN TAIWAN
NOV 30, 2017
-
CAN008 INJECTION FOR THE TREATMENT OF GBM CHINA TAIWAN PHASE I DATA RELEASING
NOV 02, 2017
-
JAMES XUE IS APPOINTED TO LEADERSHIP AND DEVELOPMENT COUNCIL MEMBER
SEP 26, 2017
-
CANBRIDGE LIFE SCIENCES APPOINTS CHIEF BUSINESS OFFICER WILL HEAD FIRST US OFFICE
SEP 12, 2017
-
CANBRIDGE CONGRATULATES APOGENIX APG101 RECEIVING EMA “PRIME” DESIGNATION
JUL 26, 2017
